J&J Finalizing Risperdal Consta Resubmission; Approval Possible By Year-End
Executive Summary
Johnson & Johnson is finalizing its response to a Risperdal Consta "not approvable" letter received from FDA last year
You may also be interested in...
Risperdal Consta Priced Aggressively; J&J Sets High Premium To Zyprexa
Johnson & Johnson's Risperdal Consta (risperidone) is being launched at approximately twice the daily cost of Lilly's market-leading antipsychotic Zyprexa (olanzapine)
Risperdal Consta Priced Aggressively; J&J Sets High Premium To Zyprexa
Johnson & Johnson's Risperdal Consta (risperidone) is being launched at approximately twice the daily cost of Lilly's market-leading antipsychotic Zyprexa (olanzapine)
J&J Risperdal Consta Priced Comparable To Zyprexa; Clears FDA Oct. 29
Johnson & Johnson has room to price its long-acting risperidone injection Risperdal Consta 40% higher than Risperdal tablets, while still remaining comparable to Lilly's Zyprexa